Ariane Tom, PhD
Founding Partner
Dr. Ariane Tom is Founding Partner of Kaleida Capital and is a frequent speaker at events where she discusses neurotechnology development and investment landscape. Prior her investment career, Ariane spent a decade at Stanford spearheading research programs in bioelectronic neural interfaces for brain-mapping, prosthetics, drug delivery, and neuromodulation. She is a published co-author in top-tier research journals Science Magazine and Nature Portfolio with Karl Deisseroth and Zhenan Bao. Ariane holds a B.S. in Materials Science & Engineering, an M.S. in Bioengineering, and a Ph.D. in Bioengineering, all from Stanford University.
Srihari Sritharan, PhD
Venture Follow
Dr. Srihari (Sri) Sritharan is a Venture Fellow at Kaleida Capital, and Director of BD at Beacon Biosignals, leveraging an EEG biomarker platform to de-risk and accelerate clinical trials for patients with neurological disorders. He was previously a Director of BD at Acadia Pharmaceuticals, leading diligence for a ~$1Bn deal with Stoke Tx to commercialize RNA therapeutics for rare diseases. During his PhD, Sri worked with Timothy Lucas and Penn Neurosurgery to develop a BCI using wireless neuromodulation to restore sense of touch in spinal cord injury patients. He has a B.S. and Ph.D. degrees in Neuroscience from Brown University and U Penn, respectively.